Figure 3. CD40L Blockade Inhibits Accumulation of Immunogenic Macrophages.
(A) Representative and quantitative flow cytometry results of recipient myeloid cell subsets in the allografts of tolerized WT recipients with or without co-treatment with agonistic CD40 mAb. Results represent mean ± SEM (n = 4 mice per group of 3 independent experiments).
(B) IFN-γ expression in cardiac allografts. Cardiac allografts were harvested 5 days after transplantation from each group. Agonistic anti-CD40 mAb was injected at 100 μg/mouse on days 0 and +1 relative to transplantation. Recombinant mouse IFN-γ was injected at 4 × 105 units/day for 10 days (n = 4 mice/group). Supernatants of single cell suspensions were analyzed for IFN-γ measured by ELISA. Bar graphs represent mean ± SEM of three independent experiments (**p < 0.01).
(C) Representative and quantitative flow cytometry results of recipient myeloid cell subsets in the allografts of tolerized CD40 deficient recipients with or without agonistic CD40 mAb treatment. Results represent mean ± SEM (n = 4 mice per group of 3 independent experiments).
(D) Effects of CD40 ligation on graft survival in tolerized WT and CD40 deficient recipients (n = 8 mice/group).
(E) Representative and quantitative flow cytometry results of recipient myeloid cell subsets in the allografts of tolerized WT recipients with or without recombinant IFN-γ treatment (4 × 105 units/day for 5 days). Results represent mean ± SEM (n = 4 mice per group of 3 independent experiments).
(F) Effects of recombinant IFN-γ on graft survival in tolerized WT recipients (n = 8 mice/group).
(G) Representative and quantitative flow cytometry results of recipient myeloid cell subsets in the allografts of tolerized WT recipients co-treated with agonistic CD40 mAb with or without anti-IFN-γ mAb treatment. Results represent mean ± SEM (n = 4 mice per group of 3 independent experiments).
(H) Effects of partial IFN-γ blockade on graft survival in tolerized wild-type recipients co treated with agonistic CD40 mAb (n = 8 mice/group).